<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00037037</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069357</org_study_id>
    <secondary_id>CPMC-IRB-13824</secondary_id>
    <secondary_id>LUDWIG-LUD00-025</secondary_id>
    <secondary_id>NCI-G02-2068</secondary_id>
    <nct_id>NCT00037037</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma</brief_title>
  <official_title>A Phase I Study of Peptide Based Vaccine Therapy in Patients With High-Risk or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may make the body build an immune response to kill&#xD;
      tumor cells. Colony-stimulating factors such as sargramostim may increase the number of&#xD;
      immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with&#xD;
      sargramostim may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy with or&#xD;
      without sargramostim in treating patients who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the safety of melanoma peptide vaccine with or without sargramostim (GM-CSF) in&#xD;
           patients with high-risk or metastatic melanoma.&#xD;
&#xD;
        -  Compare changes in peptide-specific cellular and humoral immunologic profiles in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare tumor response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive melanoma peptide vaccine comprising tyrosinase leader injected&#xD;
           at 2 separate sites, Melan-A ELA injected at another site, NY-ESO-1a and NY-ESO-1b&#xD;
           combined and injected at one site, and MAGE-10.A2 injected at another site,&#xD;
           intradermally once weekly on weeks 1-6.&#xD;
&#xD;
        -  Arm II: Patients receive vaccine as in arm I. Patients also receive sargramostim&#xD;
           (GM-CSF) subcutaneously daily beginning 2 days before each vaccination and continuing&#xD;
           for 5 days.&#xD;
&#xD;
      Treatment in both arms continues through week 6 in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients (10 per treatment arm) will be accrued for this&#xD;
      study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAGE-10.A2</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-risk stage III or IV melanoma&#xD;
&#xD;
               -  Stage III disease less than 6 months after surgical resection&#xD;
&#xD;
                    -  Completed prior interferon alfa therapy OR&#xD;
&#xD;
                    -  Progressive disease or major adverse events during prior interferon alfa&#xD;
                       therapy&#xD;
&#xD;
               -  Stage III disease at least 6 months after surgical resection&#xD;
&#xD;
                    -  Declined, failed, or completed prior standard therapy&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
                    -  Declined, failed, or completed prior standard therapy&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  No CNS metastases unless treated and stable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Lymphocyte count at least 500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL (10.0 g/dL if less than 50 kg)&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No hepatitis B or C positivity&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other serious illness&#xD;
&#xD;
          -  No serious infection requiring antibiotics&#xD;
&#xD;
          -  No history of immunodeficiency disease or autoimmune disease&#xD;
&#xD;
          -  No psychiatric or addictive disorder that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bone marrow or stem cell transplantation&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy or biologic therapy&#xD;
&#xD;
          -  No other concurrent immunotherapy or biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
          -  No concurrent steroids except topical or inhalational steroids&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  Concurrent noncytotoxic anticancer therapy allowed&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent antihistamines&#xD;
&#xD;
          -  No concurrent non-steroidal anti-inflammatory drugs except in low doses for prevention&#xD;
             of an acute cardiovascular event or pain control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos P. Papadopoulos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2004</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

